Atossa Genetics competitors

Atossa Genetics Competitors include Mirati Therapeutics, Progenics Pharmaceuticals, Merrimack Pharmaceuticals and Nektar Therapeutics.
Add company...
Atossa Genetics
Atossa Genetics
Atossa Genetics is a clinical-stage pharmaceutical company focused on the development of novel therapeutics for the treatment of breast cancer and other breast conditions.
Mirati Therapeutics
Mirati Therapeutics
Mirati Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing a pipeline of oncology products including candidates intended to treat specific genetic and epigenetic drivers of cancer in selected subsets of cancer patients with unmet needs.
Progenics Pharmaceuticals
Progenics Pharmaceuticals
Progenics Pharmaceuticals is a biopharmaceutical company focused on developing innovative therapeutics for cancer patients.
Merrimack Pharmaceuticals
Merrimack Pharmaceuticals
Merrimack Pharmaceuticals discovers, designs and develops therapies for the treatment of diseases in the areas of autoimmunity and cancer.
Nektar Therapeutics
Nektar Therapeutics
Nektar Therapeutics is a stage-clinical biopharmaceutical company.
Founding Date
Founding Date
2009
Founding Date
2013
Founding Date
1986
Founding Date
2000
Founding Date
1990
Type
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Tags
Locations
Locations
Seattle, US HQ
Locations
San Diego, US HQ
Locations
New York, US HQ
Locations
Cambridge, US HQ
Locations
San Francisco, US HQ
Hyderabad, IN
Huntsville, US
Employees
Employees
18
Employees
38
Employees
6410% increase
Employees
294
Employees
5099% increase
Valuation ($)
Valuation ($)
6.5 m
Valuation ($)
1.3 b
Valuation ($)
372.8 m
Valuation ($)
54.3 m
Valuation ($)
5.9 b
Twitter followers
Twitter followers
1.1 k
Twitter followers
101
Twitter followers
190
Twitter followers
1.1 k
Twitter followers
629

Financial

Revenue (est.)
Revenue (est.)
N/A
Revenue (est.)
N/A
Revenue (est.)
$11.7m (FY, 2017)
Revenue (est.)
N/A
Revenue (est.)
$307.7m (FY, 2017)
Net income
Net income
($8.1m) (FY, 2017)
Net income
($70.4m) (FY, 2017)
Net income
($51m) (FY, 2017)
Net income
$470.9m (FY, 2017)
Net income
($96.7m) (FY, 2017)

Funding

Total funding raised
Total funding raised
$ 7.6m
Total funding raised
N/A
Total funding raised
N/A
Total funding raised
$ 79.4m
Total funding raised
$ 45m
For sources of this data, please see the company profileDownload Excel

View company profiles

Mirati Therapeutics
HQ
San Diego, US
Employees
38

Mirati Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing a pipeline of oncology products including candidates intended to treat specific genetic and epigenetic drivers of cancer in selected subsets of cancer patients with unmet needs.

View company
Progenics Pharmaceuticals
HQ
New York, US
Employees
64↑ 10% increase

Progenics Pharmaceuticals is a biopharmaceutical company focused on developing innovative therapeutics for cancer patients.

View company
Merrimack Pharmaceuticals
HQ
Cambridge, US
Employees
294

Merrimack Pharmaceuticals discovers, designs and develops therapies for the treatment of diseases in the areas of autoimmunity and cancer.

View company
Nektar Therapeutics
HQ
San Francisco, US
Employees
509↑ 9% increase

Nektar Therapeutics is a stage-clinical biopharmaceutical company.

View company